Cargando…

Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus

Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuntao, Chen, Haiping, Lv, Jun, Huang, Tao, Zhang, Ruizhi, Zhang, Dongjuan, Luo, Linyun, Wei, Sheng, Liu, Xiaoqin, Zhang, Shangxiao, Mu, Qiuyue, Huang, Rongdong, Huang, Jiao, Xiao, Yanhui, Yang, Yunkai, Han, Yuting, Gong, Hao, Guan, Qinghu, Xie, Fangqin, Wang, Hui, Li, Liming, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/
https://www.ncbi.nlm.nih.gov/pubmed/35891184
http://dx.doi.org/10.3390/vaccines10071020
_version_ 1784754659972349952
author Zhang, Yuntao
Chen, Haiping
Lv, Jun
Huang, Tao
Zhang, Ruizhi
Zhang, Dongjuan
Luo, Linyun
Wei, Sheng
Liu, Xiaoqin
Zhang, Shangxiao
Mu, Qiuyue
Huang, Rongdong
Huang, Jiao
Xiao, Yanhui
Yang, Yunkai
Han, Yuting
Gong, Hao
Guan, Qinghu
Xie, Fangqin
Wang, Hui
Li, Liming
Yang, Xiaoming
author_facet Zhang, Yuntao
Chen, Haiping
Lv, Jun
Huang, Tao
Zhang, Ruizhi
Zhang, Dongjuan
Luo, Linyun
Wei, Sheng
Liu, Xiaoqin
Zhang, Shangxiao
Mu, Qiuyue
Huang, Rongdong
Huang, Jiao
Xiao, Yanhui
Yang, Yunkai
Han, Yuting
Gong, Hao
Guan, Qinghu
Xie, Fangqin
Wang, Hui
Li, Liming
Yang, Xiaoming
author_sort Zhang, Yuntao
collection PubMed
description Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in the diabetes group, 300 in the hypertensive combined with diabetes group (combined disease group), and 480 in the healthy population group. Two doses of the COVID-19 vaccine (Vero cell), inactivated, were administered at a 21-day interval and blood samples were collected before vaccination and 28 days after the second dose to evaluate the immunogenicity. The adverse events and changes in blood pressure and blood glucose levels after vaccination were recorded. Results: The seroconversion rate of the COVID-19 neutralizing antibodies was 100% for all participants. The post-inoculation geometric mean titer (GMT) in the four groups of the hypertension, diabetes, combined disease, and healthy populations were 73.41, 69.93, 73.84, and 74.86, respectively. The seroconversion rates and post-vaccination GMT in the hypertension, diabetes, and combined disease groups were non-inferior to the healthy population group. The rates of vaccine-related adverse reactions were 11.93%, 14.29%, 12.50%, and 9.38%, respectively. No serious adverse events were reported during the study. No apparent abnormal fluctuations in blood pressure and blood glucose values were observed after vaccination in participants with hypertension or(/and) diabetes. Conclusions: The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus.
format Online
Article
Text
id pubmed-9315836
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93158362022-07-27 Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus Zhang, Yuntao Chen, Haiping Lv, Jun Huang, Tao Zhang, Ruizhi Zhang, Dongjuan Luo, Linyun Wei, Sheng Liu, Xiaoqin Zhang, Shangxiao Mu, Qiuyue Huang, Rongdong Huang, Jiao Xiao, Yanhui Yang, Yunkai Han, Yuting Gong, Hao Guan, Qinghu Xie, Fangqin Wang, Hui Li, Liming Yang, Xiaoming Vaccines (Basel) Article Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in the diabetes group, 300 in the hypertensive combined with diabetes group (combined disease group), and 480 in the healthy population group. Two doses of the COVID-19 vaccine (Vero cell), inactivated, were administered at a 21-day interval and blood samples were collected before vaccination and 28 days after the second dose to evaluate the immunogenicity. The adverse events and changes in blood pressure and blood glucose levels after vaccination were recorded. Results: The seroconversion rate of the COVID-19 neutralizing antibodies was 100% for all participants. The post-inoculation geometric mean titer (GMT) in the four groups of the hypertension, diabetes, combined disease, and healthy populations were 73.41, 69.93, 73.84, and 74.86, respectively. The seroconversion rates and post-vaccination GMT in the hypertension, diabetes, and combined disease groups were non-inferior to the healthy population group. The rates of vaccine-related adverse reactions were 11.93%, 14.29%, 12.50%, and 9.38%, respectively. No serious adverse events were reported during the study. No apparent abnormal fluctuations in blood pressure and blood glucose values were observed after vaccination in participants with hypertension or(/and) diabetes. Conclusions: The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus. MDPI 2022-06-25 /pmc/articles/PMC9315836/ /pubmed/35891184 http://dx.doi.org/10.3390/vaccines10071020 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Yuntao
Chen, Haiping
Lv, Jun
Huang, Tao
Zhang, Ruizhi
Zhang, Dongjuan
Luo, Linyun
Wei, Sheng
Liu, Xiaoqin
Zhang, Shangxiao
Mu, Qiuyue
Huang, Rongdong
Huang, Jiao
Xiao, Yanhui
Yang, Yunkai
Han, Yuting
Gong, Hao
Guan, Qinghu
Xie, Fangqin
Wang, Hui
Li, Liming
Yang, Xiaoming
Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title_full Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title_fullStr Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title_full_unstemmed Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title_short Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
title_sort evaluation of immunogenicity and safety of vero cell-derived inactivated covid-19 vaccine in older patients with hypertension and diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/
https://www.ncbi.nlm.nih.gov/pubmed/35891184
http://dx.doi.org/10.3390/vaccines10071020
work_keys_str_mv AT zhangyuntao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT chenhaiping evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT lvjun evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT huangtao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT zhangruizhi evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT zhangdongjuan evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT luolinyun evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT weisheng evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT liuxiaoqin evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT zhangshangxiao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT muqiuyue evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT huangrongdong evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT huangjiao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT xiaoyanhui evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT yangyunkai evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT hanyuting evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT gonghao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT guanqinghu evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT xiefangqin evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT wanghui evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT liliming evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus
AT yangxiaoming evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus